^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Portrazza (necitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/15/2016
Excerpt:
Portrazza in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.
Secondary therapy:
cisplatin + gemcitabine
Source:
Title:
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
Published date:
05/20/2016
Excerpt:
Patients with pathologically confirmed stage IV sq-NSCLC...The large majority of these patients (95%) had tumor samples expressing EGFR protein...addition of necitumumab to gemcitabine–cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC.
Secondary therapy:
cisplatin
DOI:
10.1093/annonc/mdw214
Trial ID:
Source:
Title:
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Excerpt:
...- A formalin-fixed, paraffin-embedded tumor tissue block or a minimum of 5 unstained slides of tumor sample prior to randomization for the evaluation of epidermal growth factor receptor (EGFR) protein expression (IHC)....
Trial ID:
Source:
Title:
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Excerpt:
...- Participants in Cohort 1 are required to have epidermal growth factor receptor (EGFR) protein expressing tumor (defined by local immunohistochemistry test)....
Trial ID:
More C2 evidence
Source:
Title:
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
Excerpt:
...- Archived or recent tumor tissue (minimum of 5 unstained tissue slides or a paraffin-embedded tissue block) available for analysis of epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry (IHC) and other biomarker assessments...
Trial ID:
